Wall Street Loves This Eye-Drug Double Win

Monday morning, Kodiak Sciences (KOD) stopped being a quiet biotech name. It became the loudest stock on the board.

The company said two eye-disease drugs, Zenkuda and tabirafusp-ted (also called KSI-501), both hit their main goals in a late-stage study called DAYBREAK. The disease is wet age-related macular degeneration. Leaky vessels under the retina can steal central vision fast. The stock closed near $90, up about 178% on the day, after starting from the low $30s. Volume exploded. Social feeds lit up. Yahoo's U.S. trending list put KOD at the top.

I care less about the percentage and more about what the data claims to change. For years, the usual care in wet AMD has been drugs in the aflibercept family. Most people know that class through Regeneron's (REGN) Eylea franchise. Patients get shots in the eye. The treatment works. The burden is real. Anyone who has sat with a parent or spouse through those visits knows the calendar is the product as much as the medicine.

What DAYBREAK Actually Showed

DAYBREAK tested both Kodiak drugs against that real-world bar.

Zenkuda hit its main goal with a strong statistical result. It showed better vision and a drier retina. About 54% of patients landed on a six-month dosing schedule at year one under strict treat-to-dryness rules. That phrase matters. Doctors could not stretch the calendar just to make the drug look tough. They had to dry the retina first, then stretch.

Tabirafusp-ted also hit its vision goal and a key secondary goal on eye anatomy in the same study. Both arms showed very low rates of inflammation inside the eye in the company's readout. Zenkuda was at 0%. Tabirafusp-ted was near zero. Cataract rates also looked competitive versus the control arm in the topline summary.

Company doctors framed Zenkuda as fast disease control with a real shot at six-month durability under those tough rules. CEO Victor Perlroth pointed toward launch planning and a best-in-class claim. Wall Street heard "not another early biotech tease" and re-rated the stock overnight.

Why This Is Bigger Than One Trial Win

The money angle is not subtle. Wet AMD is a large, long-term market. Industry forecasts put the broader retina drug market on a path past $30 billion by the end of the decade. Doctors and patients will pay for fewer shots if the vision results hold up and the safety stays clean.

Kodiak says it plans a multi-disease filing for Zenkuda with the FDA in the fourth quarter of 2026. That package is built on five positive late-stage studies across wet AMD, diabetic eye disease, and blocked retinal veins. That is the part that turns a one-day spike into a multi-quarter story. A single wet AMD win is a catalyst. A filing across several eye diseases is a franchise attempt.

Analysts moved targets higher after the data. Several firms roughly doubled their numbers into the low triple digits. I treat those targets as mood, not math. What I watch is whether the FDA package is clean, whether insurers buy the durability claim, and whether Regeneron and other big players answer with price, convenience, or their own longer dosing.

The Risk Side Is Still Real

A biotech that nearly triples on study results can give half of it back on a footnote. Label language, factory scale-up, rival moves, and cash all matter.

Kodiak still has more late-stage work coming. That includes Phase 3 data for KSI-101 in swelling of the macula tied to inflammation, expected around December. Cash at the end of June was reported around $126 million, with runway into 2027 on earlier commentary. A company preparing a multi-disease filing and a real launch usually needs more capital, more people, and more time than the first green day implies.

There is also simple market risk. Monday's move already priced a lot of hope. If the next update is only "good, not great," or if the Street decides the durability edge is thinner than the headline, this stock can move just as hard the other way.

Bottom Line

Kodiak just put two wet AMD drugs on the board against Eylea-class care in the same late-stage study. The durability and safety profile finally made a Q4 filing path feel real. That is why the stock nearly tripled and why it topped social and Yahoo trending lists. The next chapter is not another percentage move. It is whether the FDA package, the cash plan, and the commercial story hold after the celebration ends.